Literature DB >> 27279321

Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody.

Aayush Gupta1, Yugal Kishor Sharma1, Kirti Deo1, Preeti Kothari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27279321     DOI： 10.4103/0378-6323.181466

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  5 in total

1.  Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients.

Authors:  Anchala Parthasaradhi
Journal:  J Clin Diagn Res       Date:  2016-11-01

2.  Itolizumab in Psoriasis.

Authors:  Ankita Srivastava
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

3.  Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era.

Authors:  Pugazhenthan Thangaraju; Nanditha Venkatesan; Eswaran Thangaraju; Sajitha Venkatesan
Journal:  SN Compr Clin Med       Date:  2020-09-26

4.  An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).

Authors:  Mahanjit Konwar; Mitesh R Maurya; Tushar B Nishandar; Urmila M Thatte; Nithya J Gogtay
Journal:  Perspect Clin Res       Date:  2021-01-08

5.  Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.

Authors:  Poonam Kumari; Amarjeet Kumar; Chandni Sinha; Ajeet Kumar; Prabhat K Singh; S K Arun
Journal:  Indian J Crit Care Med       Date:  2021-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.